Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with anca vasculitis

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 4, 2014, Pages 736-744

  Pendergraft, William F ^a,b   Cortazar, Frank B ^b   Wenger, Julia ^b   Murphy, Andrew P ^b   Rhee, Eugene P ^b   Laliberte, Karen A ^b   Niles, John L ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; LAMIVUDINE; MYELOBLASTIN; MYELOPEROXIDASE; PREDNISONE; RITUXIMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ANCA ASSOCIATED VASCULITIS; ARTHRALGIA; ARTICLE; BLADDER CANCER; CLINICAL ASSESSMENT; DISEASE ACTIVITY; DRUG INDUCED DISEASE; FEMALE; FEVER; HOARSENESS; HOSPITALIZATION; HUMAN; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFUSION RELATED REACTION; KAPLAN MEIER METHOD; LOG RANK TEST; LUNG CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PREGNANCY; RELAPSE; REMISSION; RETROSPECTIVE STUDY; RITUXIMAB INDUCED CONTINUOUS B CELL DEPLETION; SURVIVAL; WEANING; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; B LYMPHOCYTE; DRUG ADMINISTRATION; DRUG EFFECTS; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; RECURRENT DISEASE; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84922286333     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.07340713     Document Type: Article

References (21)

1. Jennette JC, Falk RJ, Gasim AH: Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis. Curr Opin Nephrol Hy-pertens 20: 263–270, 2011.
2. Gómez-Puerta JA, Quintana LF, Stone JH, Ramos-Casals M, Bosch X: B-cell depleting agents for ANCA vasculitides: A new therapeutic approach. Autoimmun Rev 11: 646–652, 2012.
3. Jennette JC, Falk RJ, Hu P, Xiao H: Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Annu Rev Pathol 8: 139–160, 2013.
4. Smith RM, Jones RB, Jayne DR: Progress in treatment of ANCA-associated vasculitis. Arthritis Res Ther 14: 210, 2012.
5. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vas-culitis. N Engl J Med 363: 221–232, 2010.
6. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR; European Vasculitis Study Group: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363: 211–220, 2010.
7. Mansfield N, Hamour S, Habib AM, Tarzi R, Levy J, Griffith M, Cairns T, Cook HT, Pusey CD, Salama AD: Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. Nephrol Dial Transplant 26: 3280–3286, 2011.
8. Roubaud-Baudron C, Pagnoux C, Méaux-Ruault N, Grasland A, Zoulim A, LE Guen J, Prud’homme A, Bienvenu B, de Menthon M, Camps S, LE Guern V, Aouba A, Cohen P, Mouthon L, Guillevin L; French Vasculitis Study Group: Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 39: 125–130, 2012.
9. Cartin-Ceba R, Golbin JM, Keogh KA, Peikert T, Sánchez-Menéndez M, Ytterberg SR, Fervenza FC, Specks U: Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): Ten-year experience at a single center. Arthritis Rheum 64: 3770–3778, 2012.
10. Smith RM, Jones RB, Guerry MJ, Laurino S, Catapano F, Chaudhry A, Smith KG, Jayne DR: Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vas-culitis. Arthritis Rheum 64: 3760–3769, 2012.
11. Roll P, Ostermeier E, Haubitz M, Lovric S, Unger L, Holle J, Kötter I, Henes JC, Bergner R, Rubbert-Roth A, Specker C, Schulze-Koops H, Müller-Ladner U, Fleck M, Burmester GR, Hiepe F, Heitmann S, Aringer M, Fischer-Betz R, Dörner T, Tony HP: Efficacy and safety of rituximab treatment in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides: Results from a German registry (GRAID). J Rheumatol 39: 2153–2156, 2012.
12. Rhee EP, Laliberte KA, Niles JL: Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vascu-litis. Clin J Am Soc Nephrol 5: 1394–1400, 2010.
13. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA: 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65: 1–11, 2013.
14. Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, Specks U, Allen NB, Davis JC, Spiera RF, Calabrese LH, Wigley FM, Maiden N, Valente RM, Niles JL, Fye KH, McCune JW, St Clair EW, Luqmani RA; International Network for the Study of the Systemic Vasculitides (INSSYS): A disease-specific activity index for Wegener’s granulomatosis: Modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum 44: 912–920, 2001.
15. Finkelstein DM, Muzikansky A, Schoenfeld DA: Comparing survival of a sample to that of a standard population. J Natl Cancer Inst 95: 1434–1439, 2003.
16. Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, Baslund B, Brenchley P, Bruchfeld A, Chaudhry AN, Cohen Tervaert JW, Deloukas P, Feighery C, Gross WL, Guillevin L, Gunnarsson I, Harper L, Hruskova Z, Litle MA, Martorana D, Neumann T, Ohlsson S, Padmanabhan S, Pusey CD, Salama AD, Sanders JS, Savage CO, Segelmark M, Stegeman CA, Tesar V, Vaglio A, Wieczorek S, Wilde B, Zwerina J, Rees AJ, Clayton DG, Smith KG: Genetically distinct subsets within ANCA-associated vasculitis. N EnglJ Med 367: 214-223, 2012.
17. Wall N, Harper L: Complications of long-term therapyfor ANCA-associated systemic vasculitis. Nat Rev Nephrol 8: 523-532, 2012.
18. Tesfa D, Ajeganova S, Hagglund H, Sander B, Fadeel B, Hafstrom I, PalmbladJ: Late-onset neutropenia following rituximab therapy in rheumatic diseases: Association with B lymphocyte depletion and infections. Arthritis Rheum 63: 2209-2214, 2011.
19. Venhoff N, Effelsberg NM, Salzer U, Warnatz K, Peter HH, Lebrecht D, Schlesier M, Voll RE, Thiel J: Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS One 7: e37626, 2012.
20. Bunch DO, McGregor JG, Khandoobhai NB, Aybar LT, Burkart ME, Hu Y, Hogan SL, Poulton CJ, Berg EA, Falk RJ, Nachman PH: Decreased CD5* B cells in active ANCA vasculitis and relapse after rituximab. Clin J Am Soc Nephrol 8: 382-391, 2013.
21. Wilde B, Thewissen M, Damoiseaux J, Knippenberg S, Hilhorst M, van Paassen P, Witzke O, Cohen Tervaert JW: Regulatory B cells in ANCA-associated vasculitis. Ann Rheum Dis 72:1416-1419, 2013.